The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced ...

Debio1453 is a first-in-class antibiotic candidate that targets an enzyme that’s essential for the growth of Neisseria ...

Last year, the Food and Drug Administration approved the first at-home test that can detect three common infections in women ...

The GARDP Foundation and Debiopharm have entered a collaboration and license agreement to pursue the development of a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae.

The FDA has authorized the first at-home testing kits for gonorrhea, chlamydia, and trichomoniasis, along with new gonorrhea ...

Last year, the US authorities approved the first at-home test that can detect three common infections in women — gonorrhea, ...